Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Colorectal Neoplasms × Abituzumab × Clear all

Phase

Status

Withdrawn 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 1 Prostate Cancer Metastatic 1 Colorectal and Ovarian Cancer Patients With Liver Metastases 1 Colorectal Neoplasms 1

Interventions

Fluorouracil 253 Leucovorin 223 Oxaliplatin 216 Irinotecan 204 Bevacizumab 198 Capecitabine 144 Cetuximab 135 Panitumumab 67 Folfox protocol 63 regorafenib 49 Colonoscopy 44 pembrolizumab 42 IFL protocol 39 Radiotherapy 32 Nivolumab 30 Drug Therapy 27 trifluridine tipiracil drug combination 24 Gemcitabine 24 Blood Specimen Collection 23 Chemotherapy, Adjuvant 20 Surveys and Questionnaires 19 Celecoxib 17 Surgical Procedures, Operative 16 durvalumab 15 Neoadjuvant Therapy 15 Cyclophosphamide 14 Cisplatin 14 aflibercept 13 Standard of Care 13 Pemetrexed 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01008475 2016-03-30

POSEIDON

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed

232 enrolled 20 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡